Advertisement

Cancer II pp 105-139 | Cite as

Inhibitors of Vascular Endothelial Growth Factor Receptor

  • Philip A. HarrisEmail author
Part of the Topics in Medicinal Chemistry book series (TMC, volume 28)

Abstract

Angiogenesis-targeting agents, predominantly inhibitors of vascular endothelial growth factor and its receptors, have become a mainstay in oncology practice over the last decade. The approved drugs, which include two antibodies and seven small molecule inhibitors, represent strong validation for the field of anti-angiogenesis in the treatment of cancer. In addition to ongoing clinical studies assessing new indications for these agents, novel inhibitors are undergoing clinical evaluations and combination therapies of anti-angiogenic drugs with other targeted approaches are being investigated. This chapter will review the development of the currently marketed drugs targeting VEGFR, as well as the new inhibitors currently being assessed in the clinic.

Keywords

Anti-angiogenesis Development review VEGFR inhibitors 

References

  1. 1.
  2. 2.
    Folkman J (2007) Nat Rev Drug Discov 6:273CrossRefGoogle Scholar
  3. 3.
    Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Cell Signal 19:2003CrossRefGoogle Scholar
  4. 4.
    Stuttfeld E, Ballmer-Hofer K (2009) IUBMB Life 61:915CrossRefGoogle Scholar
  5. 5.
    Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) Nat Rev Mol Cell Biol 7:359CrossRefGoogle Scholar
  6. 6.
    Ferrara N (2011) Int J Dev Biol 55:383CrossRefGoogle Scholar
  7. 7.
    Ferrara N, Hillan KJ, Gerber H-P, Novotny W (2004) Nat Rev Drug Discov 3:391CrossRefGoogle Scholar
  8. 8.
    Gordon MS, Margolin K, Talpaz M, Sledge Jr GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) J Clin Oncol 19:843CrossRefGoogle Scholar
  9. 9.
    Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Cancer Chemother Pharmacol 62:779CrossRefGoogle Scholar
  10. 10.
    Keating GM (2014) Drugs 74:1891CrossRefGoogle Scholar
  11. 11.
    Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) J Clin Oncol 23:3502CrossRefGoogle Scholar
  12. 12.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) N Engl J Med 355:2542CrossRefGoogle Scholar
  13. 13.
    Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) J Clin Oncol 28:2144CrossRefGoogle Scholar
  14. 14.
    Tewari KS, Sill MW, Long 3rd HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ (2014) N Engl J Med 370:734CrossRefGoogle Scholar
  15. 15.
    Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014) J Clin Oncol 32:1302CrossRefGoogle Scholar
  16. 16.
    Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran Jr WJ, Mehta MP (2014) N Engl J Med 370:699CrossRefGoogle Scholar
  17. 17.
    Zalcman G, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti J-J, Scherpereel A (2015) J Clin Oncol 33(Suppl); abstr 7500Google Scholar
  18. 18.
    Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Nat Rev Drug Discov 5:835CrossRefGoogle Scholar
  19. 19.
    Mangana J, Levesque MP, Karpova MB, Dummer R (2012) Exp Opin Invest Drugs 21:557CrossRefGoogle Scholar
  20. 20.
    McTigue MA, Wickersham JA, Pinko C, Showalter RE, Parast CV, Tempczyk-Russell A, Gehring MR, Mroczkowski B, Kan CC, Villafranca JE, Appelt K (1999) Structure 7:319CrossRefGoogle Scholar
  21. 21.
    McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS (2012) Proc Natl Acad Sci U S A 109:18281CrossRefGoogle Scholar
  22. 22.
    Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) J Clin Oncol 23:965CrossRefGoogle Scholar
  23. 23.
    Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O’Dwyer PJ (2006) J Clin Oncol 24:2505CrossRefGoogle Scholar
  24. 24.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) J Clin Oncol 27:3312CrossRefGoogle Scholar
  25. 25.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Cancer Res 66:11851CrossRefGoogle Scholar
  26. 26.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) N Engl J Med 359:378CrossRefGoogle Scholar
  27. 27.
    Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ (2014) Lancet 384:319CrossRefGoogle Scholar
  28. 28.
    Sun CL, Christensen JG, McMahon G (2009) Discovery and development of sunitinib (SU11248): a multitarget tyrosine kinase inhibitor of tumor growth, survival, and angiogenesis. In: Li R, Stafford JA (eds) Kinase inhibitor drugs. Wiley, Hoboken, p. 1Google Scholar
  29. 29.
    Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D (2008) Cancer Chemother Pharmacol 61:515CrossRefGoogle Scholar
  30. 30.
    Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) J Clin Oncol 24:25CrossRefGoogle Scholar
  31. 31.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) N Engl J Med 356:115CrossRefGoogle Scholar
  32. 32.
    Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Lancet 368:1329CrossRefGoogle Scholar
  33. 33.
    Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) N Engl J Med 364:501CrossRefGoogle Scholar
  34. 34.
    Harris PA, Stafford JA (2009) Discovery of pazopanib, a pan vascular endothelial growth factor kinase inhibitor. In: Li R, Stafford JA (eds) Kinase inhibitor drugs. Wiley, Hoboken, p. 57CrossRefGoogle Scholar
  35. 35.
    Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M (2007) Mol Cancer Ther 6:2012CrossRefGoogle Scholar
  36. 36.
    Hurwitz H, Dowlati A, Savage S, Fernando N, Lasalvia S, Whitehead B, Suttle B, Collins D, Ho P, Pandite L (2005) J Clin Oncol 23:3012CrossRefGoogle Scholar
  37. 37.
    Hutson TE, Davis ID, Machiels JH, de Souza PL, Baker K, Bordogna W, Westlund R, Crofts T, Pandite L, Figlin RA (2008) J Clin Oncol 26:5046CrossRefGoogle Scholar
  38. 38.
    Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) J Clin Oncol 28:1061CrossRefGoogle Scholar
  39. 39.
    Sleijfer S, Papai Z, Le Cesne A, Scurr M, Ray-Coquard I, Collin F, Pandite L, Marreaud S, De Brauwer A, Blay J (2007) J Clin Oncol 25:10031Google Scholar
  40. 40.
    van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P (2012) Lancet 379:1879CrossRefGoogle Scholar
  41. 41.
    Kania RS (2009) Structure-based design and characterization of axitinib. In: Li R, Stafford JA (eds) Kinase inhibitor drugs. Wiley, Hoboken, p. 167CrossRefGoogle Scholar
  42. 42.
    Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) J Clin Oncol 23:5474CrossRefGoogle Scholar
  43. 43.
    Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) J Clin Oncol 27:4462CrossRefGoogle Scholar
  44. 44.
    Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI (2013) Lancet Oncol 14:552CrossRefGoogle Scholar
  45. 45.
    Spano J, Chodkiewicz C, Maurel J, Wong RP, Wasan HS, Pithavala YK, Bycott PW, Liau K, Kim S, Rixe O (2007) J Clin Oncol 25:4551Google Scholar
  46. 46.
    Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E (2011) Lancet Oncol 12:256CrossRefGoogle Scholar
  47. 47.
    Davis SL, Eckhardt SG, Messersmith WA, Jimeno A (2013) Drugs Today 49:105CrossRefGoogle Scholar
  48. 48.
    Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O (2012) Clin Cancer Res 18:2658CrossRefGoogle Scholar
  49. 49.
    Grothey A, Sobrero AF, Siena S, Falcone A, Ychou M, Lenz H-J, Yoshino T, Cihon F, Wagner A, Van Cutsem E (2012) J Clin Oncol 30(Suppl 4); abstr LBA385Google Scholar
  50. 50.
    Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Joensuu H, Maki RG, Rutkowski P, Hohenberger P, Gelderblom H, Leahy MG, von Mehren M, Schoffski P, Blackstein ME, Le Cesne A, Badalamenti G, Xu J-M, Nishida T, Laurent D, Kuss I, Casali PG (2012) J Clin Oncol 30(Suppl); abstr LBA10008Google Scholar
  51. 51.
    Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L (2013) Eur J Cancer 49:3412CrossRefGoogle Scholar
  52. 52.
    Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R (2015) J Med Chem 58:1053CrossRefGoogle Scholar
  53. 53.
    Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ (2008) Cancer Res 68:4774CrossRefGoogle Scholar
  54. 54.
    Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M (2008) Int J Cancer 122:664CrossRefGoogle Scholar
  55. 55.
    Okamoto K, Ikemori-Kawada M, Jestel A, von König K, Funahashi Y, Matsushima T, Tsuruoka A, Inoue A, Matsui J (2014) ACS Med Chem Lett 6:89CrossRefGoogle Scholar
  56. 56.
    Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, Wakui H, Sasaki T, Yusa W, Fujino K, Tamura T (2015) Cancer Chemother Pharmacol 76:1153CrossRefGoogle Scholar
  57. 57.
    Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) N Engl J Med 372:621CrossRefGoogle Scholar
  58. 58.
    Sorbera LA, Serradell N, Rosa E, Bolós J, Bayés M (2007) Drugs Future 32:577CrossRefGoogle Scholar
  59. 59.
    Schmidt C (2015) J Natl Cancer Inst 107:3Google Scholar
  60. 60.
    Sahade M, Caparelli F, Hoff PM (2012) Future Oncol 8:775CrossRefGoogle Scholar
  61. 61.
    Haberkorn BC, Eskens FA (2013) Future Oncol 9:13CrossRefGoogle Scholar
  62. 62.
    Jamil MO, Hathaway A, Mehta A (2015) Curr Oncol Rep 17:24CrossRefGoogle Scholar
  63. 63.
    Benson A, Krivoshik A, Van Sant C, Needle M (2015) Ann Oncol 26(Suppl 4):108CrossRefGoogle Scholar
  64. 64.
    Porta C, Giglione P, Liguigli W, Paglino C (2015) Future Oncol 11:39CrossRefGoogle Scholar
  65. 65.
    Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L (2011) Cancer Sci 102:1374CrossRefGoogle Scholar
  66. 66.
    Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR (2012) J Clin Oncol 30:2829CrossRefGoogle Scholar
  67. 67.
    Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL (2013) J Clin Oncol 31:3517CrossRefGoogle Scholar
  68. 68.
    Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW (2013) J Clin Oncol 31:3509CrossRefGoogle Scholar
  69. 69.
    Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O’Callaghan CJ (2013) J Clin Oncol 31:2477CrossRefGoogle Scholar
  70. 70.
    Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S (2015) J Clin Oncol 33:172CrossRefGoogle Scholar
  71. 71.
    Sobrero AF, Bruzzi P (2011) J Clin Oncol 29:1938CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.GlaxoSmithKline Inc., CollegevillePAUSA

Personalised recommendations